替吉奥胶囊治疗三线及以上晚期非小细胞肺癌的临床观察

摘要

Objective To observe the efficacy and toxicity of an oral anticancer fluoropyrimidine derivative(S-1) for previously treated patients with advanced non-small cell lung cancer(NSCLC).Methods Sixty advanced NSCLC patients received secondline or further-line chemotherapy previously were enrolled in this study.Thirty cases were given S-1 orally(group A),the dosage was taken according to body surface,ranging 80mg/d to 120mg/d.Twenty-one days was a cycle.The efficacy and toxicity were evaluated after 2-cycle treatment.Another thirty cases were received best supportive care only(group B).Results In group A,there were no CR and PR case,SD was 18 cases,PD was 12 cases and the disease control rate was 60.0％ (18/30).The toxicity was mild.The main side effects were gastrointestinal reaction and bone marrow suppression.The median progression free survival(PFS) of group A and group B were 2.5 months and 2.0 months,the median overall survival(OS) were 5.0 months and 3.0 months respectively.Between the two groups,the PFS and OS was not statistically different.Conclusion S-1 exhibits modest activity and acceptable toxicity when was used as a third or subsequent line of chemotherapy in patients with advanced NSCLC.%目的 观察替吉奥胶囊单药治疗晚期非小细胞肺癌(NSCLC)的临床疗效及不良反应.方法 60例经病理组织学确诊的二线或二线以上治疗失败的NSCLC,其中30例患者(A组)据体表面积口服替吉奥胶囊(80～120mg/d,分2次口服,d1～ d14,21天为1周期),并给予最佳支持治疗,2周期后评价近期疗效和不良反应；其余30例患者(B组)仅接受最佳支持治疗.结果 A组无CR、PR病例,SD 18例,PD 12例,疾病控制率(CR+PR+SD)为60.0％ (18/30).主要不良反应为轻微的消化道反应及骨髓抑制.A组和B组的中位无进展生存期(PFS)分别为2.5个月和2.0个月,中位总生存期(0S)分别为5.0个月和3.0个月,两组差异均无统计学意义(P＞0.05).结论 替吉奥胶囊单药治疗三线及以上晚期NSCLC有一定的疗效,不良反应可以耐受,安全性良好.